GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
Merck gets two Welireg wins
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
A cautionary tale for clinical trial collaborators
AstraZeneca ended a tie-up with Asher, and then set off on its own.
